Diabetes Mellitus, Type 2
Conditions
Brief summary
The study involves 2 injections of 1.5 milligrams (mg) dulaglutide, 1 given by a pre-filled manual syringe, the other given by an auto-injector. Injections will be separated by a minimum 28-day washout period. The study will evaluate if the levels of drug in the blood are similar when given by each method. Participation in the study is likely to take approximately 7 weeks, not including screening.
Interventions
BIOLOGICALDulaglutide
Administered by subcutaneous (SC) injection
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Are overtly healthy males or females, as determined by medical history and physical examination * Male participants with female partners of child-bearing potential or partners who are pregnant or breastfeeding agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator * The method may be one of the following: * condom with spermicidal agent * male participant sterilization * true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable) * Female participants not of child-bearing potential (that is, are postmenopausal or permanently sterilized \[such as, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy\]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment * Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or spontaneous amenorrhea for 6 to 12 months, with follicle stimulating hormone (FSH) ≥40 milli-international units per milliliters (mIU/mL) * Female participants who have undergone sterilization by tubal ligation agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment * Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meters squared (kg/m\^2), inclusive, at screening * Have clinical laboratory test results within the normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have venous access sufficient to allow for blood sampling as per the protocol * Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and are willing to follow study restrictions * Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
Exclusion criteria
* Are currently enrolled in or have completed or discontinued within the last 30 days from a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study * Have known allergies to Glucagon-like peptide 1 (GLP-1) -related compounds including dulaglutide, or any components of the formulation * Are persons who have previously completed or withdrawn from this study or any other study investigating dulaglutide in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening * Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study * Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study * Have a history or presence of cardiovascular, respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data * Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician * Show evidence of significant active neuropsychiatric disease * Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC * Regularly use known drugs of abuse and/or show positive findings on urinary drug screening * Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies * Show evidence of hepatitis C and/or positive hepatitis C antibody * Show evidence of hepatitis B and/or positive hepatitis B surface antigen * Are women with a positive pregnancy test or women who are lactating * Have used or intend to use over-the-counter medication other than acetaminophen within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy \[HRT\]) within 14 days prior to dosing * Have donated blood of more than 500 milliliters (mL) within the last month * Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to adhere to the alcohol restrictions (1 unit = 12 ounces \[oz\] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) * Smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to refrain from smoking on the day of dulaglutide administration or are unable to abide by clinical research unit (CRU) restrictions * In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide | Predose to 336 hours postdose |
| Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide | Predose to 336 hours postdose |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide | Predose to 336 hours postdose |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Entire Study Population All participants who received at least one 1.5-milligram (mg) dose of dulaglutide administered subcutaneously via manual syringe or auto-injector. | 50 |
| Total | 50 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Intervention | Adverse Event | 1 | 1 |
| First Intervention | Protocol Violation | 1 | 0 |
| First Intervention | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Entire Study Population |
|---|---|
| Age, Continuous | 42.3 years STANDARD_DEVIATION 17.2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 36 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 12 Participants |
| Race (NIH/OMB) More than one race | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 35 Participants |
| Region of Enrollment United States | 50 participants |
| Sex: Female, Male Female | 10 Participants |
| Sex: Female, Male Male | 40 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 18 / 47 | 18 / 49 |
| serious Total, serious adverse events | 0 / 47 | 0 / 49 |
Outcome results
Primary
Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide
Time frame: Predose to 336 hours postdose
Population: Participants who received at least 1 dose of dulaglutide and have evaluable dulaglutide concentration data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Auto-injector | Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide | 14700 nanograms times hours per milliliters | Geometric Coefficient of Variation 22 |
| Manual Syringe | Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide | 14300 nanograms times hours per milliliters | Geometric Coefficient of Variation 24 |
Primary
Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide
Time frame: Predose to 336 hours postdose
Population: Participants who received at least 1 dose of dulaglutide and have evaluable dulaglutide concentration data.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Auto-injector | Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide | 91.1 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 31 |
| Manual Syringe | Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide | 88.2 nanograms per milliliter (ng/mL) | Geometric Coefficient of Variation 32 |
Secondary
Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide
Time frame: Predose to 336 hours postdose
Population: Participants who received at least 1 dose of dulaglutide with evaluable concentration-time data.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Auto-injector | Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide | 48.0 hours |
| Manual Syringe | Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide | 48.0 hours |